Faruqi and Faruqui, LLP Logo
Share this page

Acorda Therapeutics Inc. (ACOR)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. (“Acorda” or the “Company”) (NASDAQ:ACOR).

On August 29, 2017, Acorda announced that it had received a Refusal to File letter from the U.S. Food and Drug Administration (“FDA”), which informed the Company that its New Drug Application for INBRIJA (CVT-301) “was not sufficiently complete to permit a substantive review.”

On this news, Acorda’s share price significantly declined.

If you invested in Acorda stock or options between February 9, 2017 and August 28, 2017 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Acorda Therapeutics Inc. (ACOR)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 08/29/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.